Clinical Research Navigator: An Interactive Decision-Making Tool
Lesson 2 Decision Assistant
2.1 Observational • 2.2 Interventional • 2.3 Translational — structured, interactive planning
How to use this tool
- Observational Designer: Pick study type → get bias controls, sampling & analysis suggestions.
- Interventional Designer: Configure randomization, blinding & control → get trial skeleton & governance.
- Translational Roadmap: Map work across T0–T4 with gating deliverables.
- Outputs: Copy/print/export JSON for your notes or protocol synopsis.
- Scenarios: Prefill with solved examples to learn fast.
Note: Educational planning aid — align with sponsor SOPs, IRB/IEC, and local regulations.
Lesson goals
- Differentiate cohort, case-control, cross-sectional designs
- Plan RCTs, single-arm, crossover, factorial trials
- Bridge lab-to-clinic with T0–T4 translational milestones
Bias controlsConfoundingRandomization
BlindingEndpointsGovernance
Observational Studies Designer (Lesson 2.1)
Design & Analysis Guidance
Fill inputs and click Build Plan.
What counts as observational?
No investigator-assigned intervention. Data may be prospective (follow-up) or retrospective (records). You estimate associations, not causality.
Interventional Studies Designer (Lesson 2.2)
Trial Skeleton & Governance
Configure and click Build Trial Skeleton.
Quick reminders
- Randomization reduces selection bias; stratify on strong prognostic factors.
- Blinding reduces performance/assessment bias; if open-label, use objective endpoints and blinded adjudication.
- Register before first participant; pre-specify SAP and interims.
Translational Research Roadmap (Lesson 2.3)
Milestones, Gating Criteria & Risks
Pick a stage and click Map Milestones.
Why translational?
It connects lab discoveries to clinical impact via staged evidence and governance, ensuring relevance, safety, and feasibility.
Load Example Scenarios
Obs — High sugar & Type 2 Diabetes (Cross-sectional)
FFQ + glucose; logistic regression adjusting for age, BMI, activity, family history; stratified sampling.
RCT — Cholesterol Supplement vs Placebo
Double-blind, 1:1 block randomization; primary Δ LDL-C at 24w; ITT + ANCOVA.
Translational — Breast Cancer Diagnostic (T0→T4)
Biomarker discovery → assay validation → Ph I/II accuracy → Ph III implementation → RWE.
Cohort — Smoking & Lung Cancer
Prospective cohort; incident cancer; Cox model; careful loss-to-follow-up controls.
Outputs
Consolidated Plan
Build any section to populate this area.
Summary Tables
Observational Studies (Lesson 2.1)
| Category | Details | Examples |
|---|---|---|
| Definition | Observe outcomes without manipulating environment; natural settings. | Community BP prevalence survey. |
| Types | 1) Cohort 2) Case-control 3) Cross-sectional | Smoking→lung CA; pesticide→Parkinson’s; obesity prevalence |
| Methodologies | Data collection, sampling, analysis w/ confounder control | PROs/records; stratified sampling; logistic regression |
| Advantages | Multiple outcomes/exposures; cheaper; rare conditions; long-term | Large lifestyle cohorts |
| Limitations | Associations only; bias; confounding | Diet & cancer confounded by genetics/behavior |
Interventional Studies (Lesson 2.2)
| Category | Details | Examples |
|---|---|---|
| Definition | Active intervention to test effects on outcomes | Drug vs placebo |
| Types | RCT, Single-arm, Crossover, Factorial | Hypertension RCT; gene therapy; pain crossover; diet×exercise factorial |
| Methodologies | Randomization, blinding, control groups | Computer sequence; double-blind; SOC control |
| Advantages | Can establish causality; control confounding; robust data | Vaccine efficacy RCTs |
| Limitations | Expensive; ethics; generalizability gaps | Long oncology trials |
Translational Research (Lesson 2.3)
| Category | Details | Examples |
|---|---|---|
| Definition | Bridge lab discoveries to clinical application | Bench→therapy/diagnostics |
| Phases | T0,T1,T2,T3,T4 | Biomarkers→preclinical→Ph I/II→Ph III→RWE |
| Methodologies | Interdisciplinary, regulatory/ethics, patient involvement | Team science, FDA/EMA, advocacy groups |
| Advantages | Accelerates impact; increases relevance; fosters innovation | Rapid COVID-19 vaccine development |
| Limitations | Resource-intensive; complex coordination; regulatory hurdles | Costly oncology translation |
